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Abstract
Tetrabenazine (TBZ), a vesicular monoamine transporter-2 (VMAT-2) inhibitor
that preferentially depletes dopamine (DA), produces depressive symptoms including
motivational symptoms in humans. In rodents, it reduces selection of high-effort effort
alternatives in effort-based choice tasks, but does not affect food intake or preference
(Nunes et al. 2013; Yang et al. 2020). However, no studies have focused on the effects
of TBZ on binge-like eating to determine if it would influence “hedonic eating”. The
current study used both binge-like eating and effort-based operant tasks in rats. To
assess effects on binge-like eating, non-food restricted rats (n=8) were exposed to
chocolate over 12 sessions and their chocolate intake was recorded. Following the
initial training, rats were tested for the effects of either vehicle or 1.0 mg/kg TBZ. There
was no significant effect of 1.0 mg/kg TBZ treatment on chocolate intake. For the effects
on operant behavior, food-restricted rats (n=8) were trained on a fixed-ratio (FR)5/chow
feeding choice task. With this task, animals have a choice between lever pressing to
obtain a relatively preferred food (Bioserve pellets) or consuming a less preferred food
(lab chow) that is available in the chamber. After training, rats were tested for the effects
of injections of vehicle or 1.0 mg/kg TBZ. Administration of TBZ shifted the behavior
from lever pressing, the high-effort alternative, to chow intake. Unlike high-effort choice,
binge-like eating behavior was not affected by the depletion of DA induced by TBZ.
These results indicate that TBZ is not impairing “hedonic eating” at the dose that
reduces selection of high-effort activities such as lever pressing, further validating the
TBZ model of motivational dysfunction.
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Introduction
Motivational dysfunction
According to the National Institute of Mental Health, a 2020 study showed that an
estimated 21.0 million adults in the United States had at least one major depressive
episode, representing 8.4% of all U.S. adults (NIMH). According to the Diagnostic and
Statistical Manual of Mental Disorders (DSM-V; APA 2013), major depressive disorders
(MDD) consist of five or more of a variety of symptoms present during a two-week
period, also constituting change from the previous function. At least one of the
symptoms must be a depressed mood or loss of pleasure. Other symptoms include
significant weight loss when not dieting or weight gain, change in appetite, insomnia or
hypersomnia, thoughts of death, suicidal ideations/attempts and psychomotor agitation
or retardation nearly every day.
Despite all of these symptoms being identified, patients with MDD also suffer
from motivational problems on a daily basis affecting their employment and a variety of
other social functions (Stahl, 2002). The motivational problems mainly include
symptoms such as loss of motivation to complete tasks, anergia, and fatigue and
patients with depression are less likely to make an effort to earn a reward (Treadway et
al., 2012). There are currently six selective serotonin reuptake inhibitors (SSRIs)
approved by the Food and Drug Administration in the United States that are commonly
prescribed to treat depression, anxiety, and other mood disorders (U.S. Food and Drug
Administration). SSRIs are known to primarily increase the levels of serotonin in the
brain by blocking their reuptake into neurons (Hyttel, 1994) and some of the approved
SSRIs include citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac,
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Sarafem, Symbyax), and sertraline (Zoloft), and vilazodone (Viibryd; U.S. Food and
Drug Administration). While SSRIs are able to combat some symptoms of depression,
including mood dysfunction, rumination, and anxiety, clinical data suggests that
motivational dysfunction often remains as a debilitating symptom of this condition even
with SSRI treatment (Fava et al., 2014). These findings highlight the importance of
developing therapeutics for effort-based motivational symptoms in MDD and other
disorders to improve level of daily function and overall patient outcomes.
A variety of other mental disorders are known to display symptoms consistent
with lack of motivation. According to the DSM-V, schizophrenia is characterized by a
patient who displays two or more of the following symptoms: delusion, hallucinations,
disorganized speech, grossly disorganized or catatonic behavior, and negative
symptoms (APA 2013). Negative symptoms are the absence of behaviors typically
present in most people, for example diminished emotional expression and avolition.
Avolition, or a decrease in goal directed behavior, is a core negative symptom of
schizophrenia, interacting with the other negative symptom domains — anhedonia,
asociality, blunted affect, alogia (Strauss et al., 2021). Therefore, addressing avolition is
essential in the development of pharmaceuticals that impact the negative symptoms of
schizophrenia. Another example of a neurological disorder that affects motivation is
Parkinson’s disease. Although Parkinson’s disease is typically classified as a disease of
movement, studies show that regardless of medication status, patients with Parkison’s
disorder chose to engage less effort than control patients for the lowest reward (Chong
et al., 2015). Parkinson’s patients chose to invest more effort for a reward when they
were in the ON relative to OFF dopamine state, indicating that dopamine (DA) has a
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role in eliminating motivational deficits by promoting the exertion of effort (Chong et al.,
2015).
Overall, it is clear that motivational dysfunction is widely observed in a variety of
neurological disorders. This makes it critical to investigate therapeutics that target
motivational deficits in order to produce the most effective treatments possible for
patients suffering from these disorders.

Effort-related choice behavior
In order to understand motivational dysfunction, it is critical to define motivation
and its features. Motivation has two aspects – directional and activational. The
directional aspect is a behavior directed toward or away from a particular stimulus, for
example the appetite to consume food (Salamone and Correa, 2002). Activational
aspects are the energetic components of motivational behavior including vigor, speed,
persistence, and working to obtain food (Salamone and Correa, 2002). For example, the
persistence of an animal to obtain food is evident despite the great effort to earn the
reward of the pellet. A combination of directional and activational aspects are essential
for motivation to drive behavior. As discussed above, motivational drive and other
related functions are often inhibited as symptoms of various mental disorders, resulting
in anergia, akinesia, and fatigue. Crucially, these motivational symptoms can be
modeled in animals by utilizing effort-based choice tasks (Salamone et al., 2018) in
order to test the effectiveness of pharmacological therapeutics.
In the literature, there are several ways to utilize animal models that can measure
effort-based decision making which involve the cost-benefit analyses organisms make
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during decision making processes. This process can be studied by offering the
organism a choice between high-effort/high reward options and low-effort/low reward
options. Some examples include T-maze choice procedures where the animals have a
choice (Salamone et al., 2018) between a high food density arm which is presented with
an effort-based challenge (i.e., climbing a barrier) and a low food density arm with no
barrier. Under normal conditions, animals prefer to exert the effort of climbing the barrier
to obtain the food from the high-density arm. Another common method is the lever
pressing choice procedures with various schedules (Salamone et al., 2018). In this
paradigm, animals again have a choice between a high-effort/high-reward option in
which they can press the lever to obtain the highly preferred high carbohydrate pellets
or a low-effort/low-reward alternative which is consuming the standard laboratory chow
that is concurrently available in the chamber. For example, with a Fixed Ratio 5
(FR5)/chow feeding choice task, animals have a choice between pressing the lever five
times to obtain the relatively preferred food (Bioserve pellets), or consume the lab chow
in the chamber. At the baseline level, a healthy rat would prefer to press the lever and
obtain the preferred pellet and eat very little chow (Salamone et al., 1991). Other
examples of lever pressing choice procedures include progressive ratio (PROG)/chow
feeding choice task where the work requirement gradually increases throughout the
session (Randall et al., 2012). Similar to the T-maze task, these concurrent lever
pressing choice tasks have been validated in many ways for their ability to assess
effort-related choice behavior and numerously used in testing novel treatments.
Given the complex nature of motivational functions, it is difficult to pinpoint the
mapping between behavioral processes and neural systems, since motivational
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functions have also been shown to be related to motor processes, emotion, learning,
and other functions of the brain (Salamone & Correa, 2012). Yet, many studies showed
that specifically mesolimbic DA is necessary for certain aspects of motivational function
(Salamone and Correa, 2012). A major function of the mesolimbic DA is connecting the
psychological distance that separates an organism from motivationally significant
stimuli. In other words, when the mesolimbic DA system is interfered with, the tendency
to exert effort for food reinforcement is decreased. DA depletions or antagonism make
animals more sensitive to work requirements when it comes to instrumental tasks, like
lever pressing (Salamone and Correa, 2002). Some examples include DA receptor
antagonists such as haloperidol and ecopipam which are reported to decrease leverpressing and increase the consumption of concurrently available chow in effort-based
choice tasks when measured with FR5/chow feeding choice tasks (Cousins et al., 1994;
Sink et al., 2008). The DA antagonist haloperidol decreases lever pressing and
increases chow consumption at doses of 0.1 and 0.15 mg/kg (Cousins et al., 1994).
Additionally, rats treated with the DA D1 antagonist SCH39166 (ecopipam; 0.05–0.2
mg/kg) or the D2 antagonist eticlopride (0.025–0.1 mg/kg) showed substantial
decreases in lever pressing and increases in chow consumption (Sink et al., 2008).
These studies underline specifically that DA antagonism is leading to a low-effort bias,
which could be useful to serve as a deficit model. In Salamone Lab, DA antagonism and
DA depleting agents have been repeatedly used to induce a low-effort bias in effortbased choice tasks.

10

Tetrabenazine as a deficit model
The vesicular monoamine transporter-2 (VMAT-2), found mainly in the central
nervous system, transports the neurotransmitters serotonin, dopamine, norepinephrine,
and histamine into vesicles for storage. Tetrabenazine (TBZ) binds to VMAT-2 receptors
and acts as a reversible high-affinity inhibitor of mono-amine uptake into the granular
vesicles of the presynaptic neurons (Yero & Rey, 2008). By inhibiting this transporter,
TBZ depletes DA, reducing DA levels and allowing degradation enzymes present in the
synaptic cleft to break down DA. DA is broken down into inactive metabolites by the
enzymes monoamine oxidase (MAO), catechol-o-methyltransferase (COMT), and
aldehyde dehydrogenase (ALDH) which act in sequence (Eisenhofer et al., 2004). Once
broken down by these enzymes, the inactive DA metabolites are no longer able to act to
transmit signals in the neuron. Due to the role of TBZ in the depletion of DA, it has been
utilized to treat Huntington’s disease in order to balance the DA levels in the brain,
especially in the early hyperkinetic stage of Huntington’s disease when the DA levels
are increased in the striatum (Chen et al., 2013). In autopsy studies of Huntington’s
disease patients, patients who received TBZ displayed a greater overall depletion of DA
than patients not exposed to TBZ, in all regions studied, with the greatest reduction in
the caudate (Pearson and Reynolds, 1988). DA depletion was also found in the limbic
regions, which may explain depressive symptoms as a side effect to TBZ treatment
(Pearson and Reynolds, 1988).
Given that TBZ can induce depressive symptoms in humans, it has been
suggested to be used as a tool to alter effort-related choice behavior. Rat studies that
utilized effort-based choice tasks, such as FR5/chow feeding choice task, reported a

11

low-effort bias in lever pressing and chow intake in rats treated with 0.75 mg/kg and 1.0
mg/kg of TBZ (Nunes et al., 2013), similar to the studies with DA antagonists (Cousins
et al., 1994; Sink et al., 2008). The Salamone lab has repeatedly shown that TBZ
depletes DA, especially at the nucleus accumbens, inducing this low-effort bias in effortrelated choice behavior tasks, in which TBZ-treated rats showed a decrease in lever
pressing and increase in chow consumption (Rotolo et al., 2020; 2021). These
examples include studies showing a 1.0 mg/kg TBZ dose reliably leads to a low-effort
bias in the effort-related behavior by causing the shift from lever pressing to chow
intake. Importantly, these low-effort bias effects were reversed through treatment with
modafinil, methylphenidate, A2A antagonists, and novel DA transport (DAT) blockers
CE-123 and CE-158 (Salamone et al., 2016; Nunes et al., 2013; Rotolo et al., 2019;
2020). Rats who received TBZ treatment (0.75 mg/kg) 90 minutes prior to testing
followed by modafinil (3.75, 7.5, 15.0, 30.0 mg/kg), a DA reuptake inhibitor, 30 minutes
prior to testing showed significantly increased lever pressing relative to TBZ plus vehicle
and significantly decreased chow intake relative to TBZ plus vehicle (Salamone et al.,
2016). Additionally, rats who received TBZ treatment (0.75 mg/kg) 90 minutes prior to
testing followed by methylphenidate (0.5, 1.0, 2.0, 4.0 mg/kg), also a DA reuptake
inhibitor, 30 minutes prior to testing showed significantly increased lever pressing
relative to TBZ plus vehicle and significantly decreased chow intake relative to TBZ plus
vehicle (Salamone et al., 2016). Recently, two DAT blockers, (S)-CE-123 and (S, S)CE-158, demonstrated the ability to reverse the effort-related effects of TBZ, as well as
increase selection of high-effort PROG lever pressing in rats tested on PROG/chow
feeding choice task (Rotolo et al., 2019; 2020). At the neuronal level, when animals are
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treated with a behaviorally active dose of TBZ, there is a decrease in extracellular DA in
nucleus accumbens and changes in the expression of phosphorylated DARPP-32 in
accumbens medium spiny neurons, indicating reduced transmission at both D1 and D2
DA receptors (Nunes et al., 2013). However, when MSX-3, an A2A antagonist, is used
there is an increase in high-effort/high reward decision making (Nunes et al., 2013).
More specifically, MSX-3 was only able to counteract the effects of TBZ on pDARPP-32
(Thr34) expression, indicating that A2A receptors are colocalized with D2 and not D1
receptors (Nunes et al., 2013). These studies in combination illustrate the ability to
reverse TBZ-induced DA depletion with both DA reuptake inhibitors and A2A
antagonists.
Despite its effects on DA depletion, it is critical to note that TBZ does not alter
primary food motivation. In rat studies, TBZ did not alter food preference in free-feeding
tests (Salamone et al., 1991), and did not produce effects similar to reinforcer
devaluation by pre-feeding or appetite suppressant drugs (Randall et al., 2012; 2014).
Specifically, appetite suppressants including cannabinoid CB1 antagonists have been
found to not increase chow intake at doses that they suppress lever pressing
(Salamone et al., 2002; Sink et al., 2008). These results indicate that TBZ does not alter
appetite, but rather impacts how much effort rats are willing to exert in order to receive a
high-reward food. Similarly, TBZ does not affect sucrose appetitive taste reactivity,
sucrose consumption or preference, in free consumption tests (Pardo et al., 2015). In
this study, rats were given access to varying concentrations of sucrose (0.3%, 0.5%,
and 5%) and treated with TBZ (0, 0.5, 0.75, 1 mg/kg). At all doses of TBZ treatment,
there was no significant difference between intake of the 0.3%, 0.5%, and 5% sucrose
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reinforcers, indicating that TBZ does not impact the preference towards a certain
sucrose concentration. This enforces the idea that the low-effort bias as a result of TBZ
is based on motivation to work for a certain reinforcer, not necessarily sucrose itself.
Moreover, the effect of TBZ on feeding behavior and temporal characteristics of
responding on effort-related choice tasks has recently been investigated. During this
experiment, detailed timing of lever pressing was monitored with an event recording
system and the temporal characteristics of operant behavior was observed after
1.0 mg/kg tetrabenazine or vehicle treatments. It has been shown that TBZ increases
the feeding duration and total number of feeding bouts, however, does not affect
feeding rate or total time spent for both lever pressing to obtain pellets and consuming
chow (Ren et al., 2022). Although there was a small effect on interresponse-time (IRT)
distribution within ratios, the post reinforcement-pause (PRP) distribution was bimodal
and TBZ did not increase the duration of PRPs (Ren et al., 2022). This illustrates that
TBZ does not significantly alter consummatory motor acts involved in chow intake, but
solely alters the relative allocation of time between lever pressing and chow. These
findings again emphasize the trend that TBZ mainly affects the motivation to exert effort
(i.e., pressing the lever for a pellet) not the motor activity or the primary food motivation
required to do so.
This research demonstrates that TBZ predominantly affects the relative allocation
of lever pressing versus chow, with little impact on the overall motor activity or primary
food motivation. The intersection of these findings illustrates the precision of TBZ to
reduce the selection of high-effort rewards while increasing chow consumption,
suggesting that its interference with DA transmission leads to animals selecting lower-
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cost alternatives to obtain food, while maintaining the primary food motivation
(Salamone & Correa, 2002). Overall, these studies underline that TBZ remains a
validated measure to study motivational deficiency models in effort-related choice tasks.

Hedonic eating
Hedonic eating is a term that is commonly used in literature to describe the
consumption of highly palatable foods by rats (Salamone et al., 2022). Previous studies
have indicated that hedonic eating may involve the dopaminergic pathways emanating
from the midbrain ventral tegmental area, projecting to the nucleus accumbens in the
ventral striatum and other areas such as the amygdala, medial prefrontal cortex,
hippocampus, and hypothalamus (Kenny, 2011). Several studies have also implicated
the central DA system in a variety of human eating disorders (Bello and Hajnal, 2010).
As discussed above, DA transmission within the nucleus accumbens does not
significantly impact hedonic reactivity to different tastes, nor does it seem to affect
primary food motivation and appetite alike (Salamone & Correa, 2012). To further test
the effects of TBZ in hedonic eating, binge-like eating models can be utilized in animal
models.
Binge eating disorder (BED) is defined as an excessive intake of food within a
short period of time in combination with feelings of anxiety and shame when or about
overeating (NIMH). These episodes must occur at least once a week over a 3 month
period (DSM-5; APA 2013). BED affects approximately 2% of the US adult population,
making it important to develop animal models of palatable food consumption and food
seeking that may have relevance for BED and other conditions associated with
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excessive food intake (NIMH). In rats, this can be modeled by exposing them to a highly
palatable food (i.e., chocolate) in short intermittent periods of time (Vickers et al., 2015).
Lisdexamfetamine (LDX) is commonly used to treat BED and has been shown to affect
food intake and food-reinforced operant behavior, with larger effects when rats are
exposed to chocolate (Presby et al., 2020). LDX is a central nervous system stimulant
that increases DA levels by inhibiting its reuptake into the presynaptic neuron and
thereby increasing the release of DA into the extra neuronal space (Griffiths et al.,
2019). In Presby et al. (2020), three groups of female rats who were not restricted from
food received different food exposure conditions over several weeks: a chocolate
exposure group, a lab chow exposure group, and an empty food dish group. LDX
significantly reduced intake of both chocolate and chow in the chocolate exposure
group. In the lab chow exposure group, overall chow intake was reduced with LDX
treatment. This study provides an increased understanding of the role of increased DA
via LDX in binge-like eating behavior.
For the purpose of the present study, binge-like eating behavior is facilitated by
repeated exposure to chocolate as it represents large-scale intake of a highly palatable
food in non-restricted animals. The primary aim of this experiment is to gain a better
understanding of the role of DA depletion by TBZ in “hedonic eating” that is modeled by
utilizing highly palatable food intake in rats. TBZ will also be tested on and operant
effort-based choice task to further understand its influence on effort-based choice
behavior. It is hypothesized that TBZ is not reducing “hedonic eating” at the doses that
induce a reduction in high-effort/high-reward selection.
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Materials and Methods
Animals
Adult, male Sprague Dawley rats (Envigo, Indianapolis, IN, USA) were housed in
a colony maintained at 23 °C with 12-h light/dark cycles (lights on 07:00). Rats (n = 8 for
the operant training; n = 8 for binge-like eating model) weighed 275–299 g at the
beginning of the study. The operant training group was initially food restricted to 85% of
their free-feeding body weight for operant training with a modest weight gain throughout
the experiment. Rats were fed supplemental chow to maintain weight throughout the
study, with water available ad libitum. Animal protocols were in accordance with
University of Connecticut Institutional Animal Care and Use Committee guidelines.

Development of chocolate binge eating behavior
Ground Cadbury's Dairy Milk Chocolate composed of 0.3 g fat, 0.57 g
carbohydrate, and 0.073 g protein with a total of 5.34 kcal/g was utilized in the
development and maintenance of binge like eating behavior. To develop binge-like
eating behaviors, rats were initially exposed to 1-hour sessions in an empty feeding
cage with a ceramic dish for 3 days. Following this initial exposure, the rats had 12
exposure sessions for 1 hour each in an empty feeding cage with a ceramic dish
containing ground chocolate. These chocolate exposures took place on days 1, 2, 4, 5,
7, 8, 12, 14, 15, 18, 23, and 28 in which the amount of chocolate consumed was
recorded after each session (Presby et al., 2020). The weights of the rats and
consumed home-cage laboratory chow were recorded daily. Water in the home cage
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was provided ad libitum throughout the experiment. After the initial training, drug
experiments had started.

Behavioral procedure of operant training
The rats were trained in a fixed ratio (FR) 5/chow feeding choice task. Using Med
Associates operant chambers (28 × 23 × 23 cm), rats were trained with the following
schedule – 3 days of magazine training, followed by 3 days of FR 1. After, the rats were
trained to lever press for the plain high carbohydrate pellets on a FR5 schedule for 5
weeks which was followed by FR5/choice training for another 5 weeks. Lab chow (5P00
ProLab RMH 3000; ScottPharma Solutions) was used during the exposure sessions,
operant task, and non-food restriction phase, and was composed of approximately 14%
fat, 60% carbohydrate and 26% protein with a total of 4.18 kcal/g. For the operant task,
the pellets (Dustless Precision Pellets, 45 mg, Rodent Purified Diet; Bio-Serv) were
composed of 5.5% fat, 59.1% carbohydrate and 18.4% protein with a total of 3.6 kcal/g.
Water in the home cage was provided ad libitum throughout the experiment. After the
initial training, drug experiments had started.
Drug treatment
TBZ (Tocris Bioscience) was dissolved in a solution of 20% dimethylsulfoxide
(DMSO) and 0.9% saline prior to each drug treatment. It was then titrated with 1N HCl
resulting in a pH of about 4.5. In order to formulate the vehicle (VEH) solution, 20%
DMSO and 80% saline were combined with an equal amount of HCl to maintain the
same volume as the TBZ solution.
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Experimental design
Experiment 1
Following the completion of the binge-like eating training, rats experienced two
sessions in the empty feeding cage with the ceramic dish containing chocolate for 1
hour each week. Their weights and their home cage lab chow intake were recorded
Monday through Friday. A repeated measure design was used to assess the drug
effects. After the completion of this phase, rats were injected with VEH or 1.0mg/kg TBZ
120 minutes prior to the beginning of the experiment which took place once a week, on
Thursday or Friday. The amount of chocolate consumption was recorded after the
conclusion of each exposure.
Experiment 2
A repeated measure design was used to assess the drug effects. After the
completion of the operant training, another set of rats were injected with 1.0 mg/kg of
TBZ or VEH 120 minutes before the beginning of the experiment. This was performed
over consecutive weeks in a randomized order in which drug experiments were
conducted on Thursday or Friday. For each session, the lever pressing and chow intake
were then recorded after each run.

Statistical analysis
A paired sample t-test was used to compare the TBZ and VEH conditions for
each binge-like eating behavior and operant task by using Statistical Package for the
Social Sciences version 28 (SPSS; IBM).
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Results
For the binge-like eating behavior, there was no significant difference in
chocolate intake for TBZ (M = 7.075, SD = 0.500546576) and VEH (M = 6.45, SD =
0.744773455), t(7) = -0.625, p = 0.420 (Figure 1).

Figure 1. The effects of tetrabenazine on chocolate intake in binge-eating behavioral
model (n=8). Mean (±SEM) chocolate intake during the 1-hour exposure session. There
was no statistically significant difference between 1.0 mg/kg TBZ and VEH chocolate
intake.

For the operant behavior, there was a significant difference in lever pressing for
TBZ (M = 367.3750, SD = 411.98611) and VEH (M = 1416.125, SD = 261.38064), t(7) =
4.806, p = 0.002 (Figure 2). There was a significant difference in chow intake for TBZ
(M = 5.5125, SD = 2.50681) and VEH (M =0.9500, SD = 0.89443), t(7) = -6.111, p = <
0.001 (Figure 3).
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Figure 2. The effects of tetrabenazine on lever pressing in the FR5/chow feeding choice
task effort related decision-making (n=8). Mean (±SEM) number of total lever presses
during the 30-minute operant session, in which *p = 0.002: statistically significant
difference between 1.0 mg/kg TBZ and VEH on number of lever presses.

Figure 3. The effects of tetrabenazine on chow intake in the FR5/chow feeding choice
task effort related decision-making (n=8). Mean (±SEM) chow intake during the 30-
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minute operant session, in which *p = 0.002: statistically significant difference 1.0 mg/kg
TBZ and VEH chow intake.

Discussion
The aim of this study was to determine if TBZ reduces “hedonic eating” at the
doses that induce a reduction in high-effort/high-reward selection. As hypothesized,
there was not a statistically significant difference between chocolate intake with TBZ
treatment (Figure 1), helping us understand the effects of TBZ in hedonic eating by
modeling binge-eating behavior. Treatment with TBZ resulted in a statistically significant
decrease in lever pressing (Figure 2) and increase in chow intake (Figure 3). This
illustrates that low-effort bias induced by impairment of DA transmission, in this case by
TBZ, is not a result of lack of primary food motivation or “anhedonia”.
These findings concur with a wide variety of research that DA transmission does
not affect hedonic activity or primary food motivation, it is involved in specific functions
of motivation and exertion of effort (Salamone and Correa, 2012). Moreover, it has been
discussed that interference with DA transmission leaves the primary food motivation
and food reinforcement intact (Salamone and Correa, 2002). Previous studies have
consistently shown that DA antagonism and depletion in rats does not alter their
hedonic taste reactivity to sucrose, as well as sucrose preference in general (Berridge &
Robinson, 1998). The findings concur with previous studies involving the effects of TBZ
including pre-feeding in which animals are fed the day before of their operant run, or
with appetite-suppressant drugs such as CB1 agonists (Randall et al., 2012, 2014;
Salamone et al., 2002; Sink et al., 2008). In addition, TBZ has been found to not
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influence the food and sucrose preferences in rats (Nunes et al., 2013; Pardo et al.,
2015). In a recent study, TBZ also has shown to not alter feeding rate or time allocated
to feeding during operant tasks, FR5/chow feeding choice task (Ren et al., 2022). In all
of these examples it is clear that DA depletion by TBZ is not affecting “hedonic eating”
or altering the primary feeding motivation. In the present study, treatment with TBZ did
not change the intake of a highly palatable food, such as chocolate, that was presented
for a short duration of time. In fact, TBZ animals show a slight increase in their
chocolate consumption compared to vehicle condition rats, further suggesting that TBZ
is not affecting hedonic eating.
Although it has been shown that TBZ does not affect primary food motivation,
preference, or hedonic eating as discussed above, it does influence the exertion of
effort as tested in effort-based decision-making tasks. In baseline conditions, the rats
prefer to press the lever to get the highly palatable food, Bioserve pellets, and eat little
chow in FR5/chow feeding choice tasks. As has been shown many times in literature,
1.0mg/kg dose of TBZ induces a low-effort bias, when tested in FR5/chow feeding
choice tasks (Rotolo et al., 2020; 2021) in which TBZ treated rats have lower lever
pressing but increased chow intake. In the current study, this finding was replicated and
TBZ treatment of rats decreases lever pressing and increases chow intake in FR5/chow
feeding choice task in comparison to the vehicle condition. It is important to note that
when there is a decrease in lever pressing, there is an increase in the concurrently
available chow intake in all the aforementioned studies utilizing TBZ, underlining the fact
that it is not altering the primary food motivation. However, the same dose that leads to
a shift in choice behavior, did not alter chocolate consumption in free-feeding animals
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as measured by the chocolate intake in binge-like eating behavior model. Importantly,
the fact that TBZ treatment did not significantly impact chocolate intake in the bingeeating model and only led to a low-effort bias, shows TBZ primarily affects the choice
behavior. This highlights the role of TBZ treatment in inducing low-effort bias in effortrelated choice tasks, making it a valid model of motivational dysfunction.
As with any scientific experiment, there were several limitations to this study.
Although the use of rodent models has been essential for understanding the
pathogenesis of many human diseases, including BED, it is difficult to model all features
of human BED in rat models (Corwin and Buda-Levin, 2004; Perello et al., 2010). Most
notably, these models measure the objective characteristics of binge-eating, the
consumption of a large amount of food over a short period of time, and exclude
subjective characteristics including the feeling of loss of control felt by patients with BED
(Perello et al., 2014). A significant weakness in studying MDD in rats is that this is a
short-term application of depression, which is very different from the long-lasting cases
of human MDD (Nestler & Hyman, 2010). It is important to acknowledge these
limitations when considering the results of this study.
Due to the high incidence of depression in our country and world, it is highly
important that we continue to investigate the fine details of the symptoms experienced
during major depressive episodes, especially motivational symptoms. The results of this
study may indicate having healthy options readily available for individuals during major
depressive episodes may better their overall health. By showing TBZ is not altering
hedonic eating, TBZ treatment is validated as an animal model for effort-related

24

motivational symptoms observed in many disorders including depression. This study
further allows the usage of TBZ as a motivational dysfunction model in rats.
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